Collegium Q4 revenue up 13% but slightly misses estimates

Collegium Pharmaceutical

26/02/2026 12:43

Overview

Biopharmaceutical firm's Q4 revenue rose 13% yr/yr but slightly missed analyst expectations

Adjusted EPS for Q4 improved compared to the previous year

In ADHD business, Jornay PM net revenue grew 57% yr/yr in Q4

Outlook

Collegium reaffirms full-year 2026 guidance for product revenues at $805 to $825 mln

Company expects Jornay PM revenue between $190 mln and $200 mln for 2026

Collegium projects adjusted EBITDA of $455 mln to $475 mln for 2026

Result Drivers

JORNAY PM GROWTH - Co reported a 57% increase in Jornay PM net revenue for Q4, driven by strategic investments and increased prescriber numbers

PAIN PORTFOLIO PERFORMANCE - Pain portfolio net revenues grew 5% in Q4, with mixed results across individual products

STRATEGIC INVESTMENTS - Co attributed growth to strategic investments in sales force expansion and marketing for Jornay PM

Company press release: ID:nGNX4wKBy9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Miss*
$205.40 mln
$206.36 mln (5 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Collegium Pharmaceutical Inc is $56.00, about 22.4% above its February 25 closing price of $45.75

The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)